Polygenic Score (PGS) ID: PGS001800

Predicted Trait
Reported Trait Forced expiratory volume (FEV1)
Mapped Trait(s) forced expiratory volume (EFO_0004314)
Released in PGS Catalog: Dec. 10, 2021
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name PRS_FEV1
Development Method
Name lassosum
Parameters Genotyped or well-imputed variants (r2 > 0.5). Can be combined with PGS001801(PRS_Ratio) to predict COPD (see performance metrics for details).
Variants
Original Genome Build GRCh37
Number of Variants 1,713,430
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000264
Citation (link to publication) Moll M et al. Lancet Respir Med (2020)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
321,047 individuals (100%)
Score Development/Training
European: 100%
1,528 individuals (100%)
PGS Evaluation
European: 66.7%
African: 16.7%
Multi-ancestry (excluding European): 16.7%
  • African
  • Not Reported
  • East Asian
  • Hispanic or Latin American
6 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST007432
Europe PMC: 30804560
 321,047 individuals European UKB
Score Development/Training
Study Identifiers Sample Numbers Sample Ancestry Cohort(s) Phenotype Definitions & Methods Age of Study Participants Participant Follow-up Time Additional Ancestry Description Additional Sample/Cohort Information
—
[
  • 692 cases
  • , 836 controls
]
 European GenKOLS Moderate-to-severe COPD (FEV1/FVC <0·7 and FEV1 <80% of predicted) — — — —

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM009319 PSS007723|
Multi-ancestry (excluding European)|
7,122 individuals
 PGP000264 |
Moll M et al. Lancet Respir Med (2020)
 Reported Trait: Chronic obstructive pulmonary disease (moderate-to-severe) — — Odds Ratio of Combined PRS (OR): 1.42 [1.34, 1.51) Age, sex, height, smoking pack-years, PCs of genetic ancestry, study clinic, PRS_Ratio NOTE: A combined PRS is used to account for both PRS. The combined score can be derived using code from: http://www.copdconsortium.org/polygenic-risk-score
PPM009316 PSS007721|
European Ancestry|
5,175 individuals
 PGP000264 |
Moll M et al. Lancet Respir Med (2020)
 Reported Trait: GOLD spirometry grades — — Association (p-value): 4.54e-43 — —
PPM009318 PSS007722|
European Ancestry|
19,229 individuals
 PGP000264 |
Moll M et al. Lancet Respir Med (2020)
 Reported Trait: Chronic obstructive pulmonary disease (moderate-to-severe) — — Odds Ratio of Combined PRS (OR): 1.81 [1.74, 1.88] Age, sex, height, smoking pack-years, PCs of genetic ancestry, study clinic, PRS_Ratio NOTE: A combined PRS is used to account for both PRS. The combined score can be derived using code from: http://www.copdconsortium.org/polygenic-risk-score
PPM015563 PSS009985|
European Ancestry|
6,647 individuals
 PGP000385 |
Zhang J et al. Eur Respir J (2022)
|Ext.		 Reported Trait: Incident chronic obstructive pulmonary disease before age 50 years OR: 1.55 [1.41, 1.71] AUROC: 0.739 [0.718, 0.761] — PGS001801, early-life risk factors, principal components of genetic ancestry NOTE: A combined PRS is used to account for both PRS. The combined score can be derived using code from: http://www.copdconsortium.org/polygenic-risk-scor
PPM015564 PSS009983|
African Ancestry|
2,464 individuals
 PGP000385 |
Zhang J et al. Eur Respir J (2022)
|Ext.		 Reported Trait: Incident chronic obstructive pulmonary disease before age 50 years OR: 1.23 [1.05, 1.43] AUROC: 0.635 [0.595, 0.675] — PGS001801, early-life risk factors, principal components of genetic ancestry NOTE: A combined PRS is used to account for both PRS. The combined score can be derived using code from: http://www.copdconsortium.org/polygenic-risk-scor
PPM015565 PSS009984|
European Ancestry|
6,812 individuals
 PGP000385 |
Zhang J et al. Eur Respir J (2022)
|Ext.		 Reported Trait: Incident chronic obstructive pulmonary disease before age 50 years OR: 2.47 [2.12, 2.88] — — PGS001801, early-life risk factors, principal components of genetic ancestry NOTE: A combined PRS is used to account for both PRS. The combined score can be derived using code from: http://www.copdconsortium.org/polygenic-risk-scor

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS007721 — — 5,175 individuals,
52.27 % Male samples
 — European — COPDGene —
PSS007722 — —
[
  • 3,065 cases
  • , 2,110 controls
]
,
52.27 % Male samples
 — European — COPDGene Fixed-effects meta-analysis
PSS007722 — —
[
  • 609 cases
  • , 1,480 controls
]
,
36.19 % Male samples
 — European — CHS Fixed-effects meta-analysis
PSS007722 — —
[
  • 1,713 cases
  • , 147 controls
]
,
66.34 % Male samples
 — European — ECLIPSE Fixed-effects meta-analysis
PSS007722 — —
[
  • 1,809 cases
  • , 946 controls
]
,
63.74 % Male samples
 — European — LHS Fixed-effects meta-analysis
PSS007722 — —
[
  • 208 cases
  • , 948 controls
]
,
47.66 % Male samples
 — European — MESA Fixed-effects meta-analysis
PSS007722 — —
[
  • 371 cases
  • , 429 controls
]
,
83.12 % Male samples
 — European — NAS, NETT Fixed-effects meta-analysis
PSS007722 — —
[
  • 127 cases
  • , 911 controls
]
,
42.87 % Male samples
 — European — RS Fixed-effects meta-analysis
PSS007722 — —
[
  • 96 cases
  • , 867 controls
]
,
46.73 % Male samples
 — European — RS Fixed-effects meta-analysis
PSS009983 Age of diagnosis was defined using age at earliest exam when moderate-to-severe COPD (modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 2–4 using pre-bronchodilator spirometry) was observed. We defined COPD occurring early in life as age at diagnosis <50 year — 2,464 individuals,
57.6 % Male samples
 — African American or Afro-Caribbean
(African American)		 — COPDGene —
PSS007722 — —
[
  • 988 cases
  • , 537 controls
]
,
52.85 % Male samples
 — European — SPIROMICS Fixed-effects meta-analysis
PSS007723 — —
[
  • 910 cases
  • , 1,556 controls
]
,
57.62 % Male samples
 — African American or Afro-Caribbean — COPDGene Fixed-effects meta-analysis
PSS007723 — —
[
  • 116 cases
  • , 258 controls
]
,
34.49 % Male samples
 — African American or Afro-Caribbean — CHS Fixed-effects meta-analysis
PSS007723 — —
[
  • 794 cases
  • , 1,600 controls
]
,
74.56 % Male samples
 — Not reported — NR Fixed-effects meta-analysis
PSS007723 — —
[
  • 115 cases
  • , 645 controls
]
,
46.58 % Male samples
 — African American or Afro-Caribbean — MESA Fixed-effects meta-analysis
PSS007723 — —
[
  • 31 cases
  • , 422 controls
]
,
49.89 % Male samples
 — East Asian — MESA Fixed-effects meta-analysis
PSS007723 — —
[
  • 62 cases
  • , 613 controls
]
,
47.26 % Male samples
 — Hispanic or Latin American — MESA Fixed-effects meta-analysis
PSS009985 Age of diagnosis was defined using age at earliest exam when moderate-to-severe COPD (modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 2–4 using pre-bronchodilator spirometry) was observed. We defined COPD occurring early in life as age at diagnosis <50 year — 6,647 individuals,
52.3 % Male samples
 — European
(Non-Hispanic White)		 — COPDGene —
PSS007722 — —
[
  • 131 cases
  • , 1,737 controls
]
,
43.36 % Male samples
 — European — RS Fixed-effects meta-analysis
PSS009984 Age of diagnosis was defined using age at earliest exam when moderate-to-severe COPD (modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 2–4 using pre-bronchodilator spirometry) was observed. We defined COPD occurring early in life as age at diagnosis <50 year — 6,812 individuals — European — FHS —